Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QL1706 alone or with bevacizumab + XELOX as first-line treatment for unresectable locally advanced or metastatic colorectal cancer
CTR20221438Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in colorectal cancer (CRC), sponsored by Qilu Pharmaceutical. Started Sep 2022; status: active.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20221438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221438.